A study of more than 80,000 people with type 2 diabetes found higher rates of heart attacks, strokes and deaths among those who stopped GLP-1 drugs than among those who continued treatment. Stopping popular diabetes and weight-loss drugs known as GLP-1 receptor agonists may be associated with nearly twice the risk of a heart attack, stroke or death compared with continuing treatment, according to a new study published in The Lancet Regional.